Swiss National Bank Invests $1.28 Million in Assembly Biosciences Inc (ASMB) Stock
Swiss National Bank bought a new stake in Assembly Biosciences Inc (NASDAQ:ASMB) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 28,300 shares of the biopharmaceutical company’s stock, valued at approximately $1,281,000.
A number of other large investors have also recently bought and sold shares of ASMB. Nationwide Fund Advisors acquired a new position in Assembly Biosciences in the 2nd quarter valued at about $161,000. Parametric Portfolio Associates LLC boosted its holdings in Assembly Biosciences by 13.6% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 10,078 shares of the biopharmaceutical company’s stock valued at $208,000 after purchasing an additional 1,203 shares during the last quarter. Wells Fargo & Company MN acquired a new position in Assembly Biosciences in the 2nd quarter valued at about $213,000. The Manufacturers Life Insurance Company boosted its holdings in Assembly Biosciences by 15,448.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,195 shares of the biopharmaceutical company’s stock valued at $232,000 after purchasing an additional 11,123 shares during the last quarter. Finally, Teacher Retirement System of Texas acquired a new position in Assembly Biosciences in the 4th quarter valued at about $242,000. Institutional investors own 77.26% of the company’s stock.
Several equities analysts have weighed in on ASMB shares. Zacks Investment Research upgraded shares of Assembly Biosciences from a “hold” rating to a “buy” rating and set a $37.00 target price on the stock in a report on Wednesday, November 15th. BidaskClub lowered shares of Assembly Biosciences from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 6th. ValuEngine lowered shares of Assembly Biosciences from a “hold” rating to a “sell” rating in a report on Thursday, December 7th. B. Riley started coverage on shares of Assembly Biosciences in a report on Friday, January 5th. They issued a “neutral” rating and a $35.00 target price on the stock. Finally, Jefferies Group boosted their target price on shares of Assembly Biosciences to $75.00 and gave the company a “buy” rating in a report on Thursday, March 8th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $54.25.
Shares of Assembly Biosciences Inc (ASMB) opened at $63.87 on Wednesday. Assembly Biosciences Inc has a 52 week low of $18.60 and a 52 week high of $67.36.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2018/03/14/swiss-national-bank-invests-1-28-million-in-assembly-biosciences-inc-asmb-stock.html.
Assembly Biosciences Profile
Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.
Want to see what other hedge funds are holding ASMB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Assembly Biosciences Inc (NASDAQ:ASMB).
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.